{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:57:00Z","timestamp":1783763820887,"version":"3.55.0"},"reference-count":19,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2014,5,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We report a case of a 56-year-old woman with a high-grade diffuse large B-cell lymphoma who unexpectedly developed toxic plasma levels of methotrexate (MTX) following the first cycle of rituximab-cyclophosphamide, hydroxydanorubicin, oncovin, prednisolone (R-CHOP) with a high-dose MTX chemotherapy protocol. She also developed non-oliguric acute kidney injury secondary to MTX nephrotoxicity. We elected to treat her with online-haemodiafiltration (HDF) and this proved to be efficient with a dramatic response. Rapid clearance of MTX to therapeutic levels was possible within three sessions. Prompt therapy with high-volume online-HDF is an effective choice for rapid MTX clearance and swift reversal of MTX nephrotoxicity.<\/jats:p>","DOI":"10.1136\/bcr-2014-203530","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T10:32:29Z","timestamp":1400841149000},"page":"bcr2014203530","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["The utility of online haemodiafiltration in methotrexate poisoning"],"prefix":"10.1136","volume":"2014","author":[{"given":"Mohamed Said","family":"Abdelsalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3158-8316","authenticated-orcid":false,"given":"Mohammed Mahdi","family":"Althaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Alfurayh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Maghfoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,5,23]]},"reference":[{"issue":"(5 Suppl 18)","key":"2025042705240118000_2014.may23_1.bcr2014203530.1","first-page":"S18-30","article-title":"Folate and antifolate pharmacology","volume":"24","author":"Kamen","year":"1997","journal-title":"Semin Oncol"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-002-0946-7"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90384-4"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880901)62:5<884::AID-CNCR2820620506>3.0.CO;2-A"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00262416","article-title":"Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients","volume":"3","author":"Evans","year":"1979","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.6","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.06.068"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.9","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.1.111"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM197501092920216","article-title":"Letter: limitations of methotrexate and citrovorum-factor treatments","volume":"292","author":"Frei","year":"1975","journal-title":"N Engl J Med"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20255"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.13","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050528"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.14","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005060-00005"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.15","doi-asserted-by":"publisher","DOI":"10.1159\/000185335"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.16","doi-asserted-by":"publisher","DOI":"10.1159\/000188722"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.17","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050656"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-11-1299"},{"key":"2025042705240118000_2014.may23_1.bcr2014203530.19","doi-asserted-by":"publisher","DOI":"10.1038\/2121548a0"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2014-203530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:24:08Z","timestamp":1745756648000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2014-203530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,23]]},"references-count":19,"alternative-id":["10.1136\/bcr-2014-203530"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2014-203530","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,23]]}}}